Cure8 news brief
Long-term Phase 3 extension data suggest guselkumab (Tremfya) may provide sustained clinical and endoscopic remission for some adults with moderate-to-severe Crohn's disease, which could expand treatment options for patients who have not responded to other therapies.
Adults with Crohn's disease, patients considering or currently on biologic therapy, gastroenterologists, and researchers following IL-23 inhibitors and long-term Crohn's outcomes.
The report highlights high clinical remission rates at three years in patients remaining on study treatment, plus meaningful endoscopic remission percentages and high corticosteroid-free remission. Safety through Week 144 was reported as consistent with prior experience.
The findings are presented as long-term extension data from Phase 3 programs (GALAXI 2 and 3) and were presented at the ACG 2026 meeting, per the article.
Before making treatment decisions, patients should discuss with their gastroenterologist whether these trial populations and dosing schedules match their situation, and should review full study results (peer-reviewed publication or conference poster/abstract) for detailed methods, intent-to-treat analyses, and safety event rates.
This RTTNews item summarizes company-reported data presented at a conference. Full study details, peer-reviewed publication, and independent assessment of safety and efficacy across the enrolled population are needed to understand generalizability.
Reported percentages reflect patients in the LTE analysis as described by the source; they are not a substitute for regulated labeling or clinical guidance.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
The article summarizes recent drug approvals and Phase 3 trial results that could affect which biologic treatments are available and how the Crohn's disease treatment market may change. It also gives epidemiology and...
The article summarizes a commercial market report that lists current and upcoming Crohn's disease treatments, trial results, and a biosimilar approval — information patients may see reflected in treatment availability,...
Long-term control of symptoms and intestinal inflammation is a major need in Crohn's disease. Three-year data showing sustained clinical and endoscopic remission and high rates of steroid-free remission could be...
